OR WAIT null SECS
On the HCPLive inflammatory bowel disease page, resources on the topics of medical news and expert insight into IBD can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBD and more.
October 30, 2026
Video
Marla Dubinsky, MD, discusses phase 3 SHINE-2 data showing mirikizumab induced clinical remission in 41.3% of children with UC by week 12.
October 19, 2026
David Rubin, MD, discusses GALAXI and GRAVITI data showing guselkumab improved non-passable intestinal stenosis in Crohn’s disease through 2 years.
October 15, 2026
Mirikizumab LUCENT data from UEG Week 2026: 27.7% reached comprehensive disease control at week 52, with high IBDQ remission rates.
VIVID-1 post hoc data from UEG Week 2026: about 1 in 5 patients reached steroid-free deep remission at 1 year, tied to IBDQ remission.
October 14, 2026
Article
In pooled, propensity-matched data, SC infliximab achieved week 54 endoscopic response in 65.7% of patients with ileal Crohn’s disease vs 27.1% with IV.
Phase 3 SHINE-2 data show 41.3% of children and adolescents with UC reached clinical remission after 12 weeks of mirikizumab induction.
October 13, 2026
David Rubin, MD, discusses QUASAR extension data showing most patients in histologic remission on guselkumab stayed there through 3 years of maintenance.
In a LIBERTY post hoc analysis, most patients restarting infliximab as SC 240 mg after a drug holiday had prior ADAs, yet outcomes were similar.
Maria Abreu, MD, discusses 76-week ANTHEM-UC extension data showing once-daily oral icotrokinra maintained efficacy with no new safety signals in UC.
October 12, 2026
Post hoc FORTIFY OLE analyses presented at ACG 2026 show sustained remission across disease locations and rising no-draining-fistula rates over 5 years.